1. Introduction {#sec1-ijms-20-03355}
===============

Gastric cancer (GC) is one of the most common forms of cancer worldwide. Despite a steady decline in GC incidence and mortality rates over the past few decades, the rates are still high in Asian countries. According to a report by the Korean National Cancer Center, GC is the third most common cancer, with 25,872 new cases and 7138 deaths recorded in Korea in 2016 \[[@B1-ijms-20-03355],[@B2-ijms-20-03355],[@B3-ijms-20-03355]\].

Approximately 80% of disease-related polymorphisms occur in non-coding regions consisting of introns and intergenic regions \[[@B4-ijms-20-03355]\]. Genome-wide association studies have reported that a large number of polymorphisms are associated with cancer and that these cancer-related polymorphisms are associated with long non-coding RNAs (lncRNAs) \[[@B5-ijms-20-03355],[@B6-ijms-20-03355],[@B7-ijms-20-03355]\]. LncRNAs are non-translated RNA molecules over 200 nucleotides in length. Recently, it was reported that lncRNAs are involved in tumorigenesis \[[@B8-ijms-20-03355],[@B9-ijms-20-03355]\]. Moreover, germline variants can affect lncRNA expression, regulating cancer development and progression \[[@B10-ijms-20-03355]\]. Indeed, several studies have demonstrated that lncRNA genetic variants are related to susceptibility of various cancers, including breast cancer \[[@B11-ijms-20-03355],[@B12-ijms-20-03355]\], colon cancer \[[@B13-ijms-20-03355]\], gastric cancer \[[@B14-ijms-20-03355],[@B15-ijms-20-03355]\], lung cancer \[[@B16-ijms-20-03355]\], and prostate cancer \[[@B10-ijms-20-03355],[@B17-ijms-20-03355]\]. Particularly, lncRNA prostate cancer non-coding RNA 1 (*PRNCR1*), transcribed from a non-coding region of chromosome 8q24, is involved in the carcinogenesis of prostate cancer (PC) through activation of the androgen receptor \[[@B18-ijms-20-03355]\], and lncRNA *PRNCR1* polymorphisms have been correlated with various cancers, including GC \[[@B14-ijms-20-03355],[@B18-ijms-20-03355],[@B19-ijms-20-03355],[@B20-ijms-20-03355],[@B21-ijms-20-03355],[@B22-ijms-20-03355],[@B23-ijms-20-03355]\].

Based on previous findings, we hypothesized that polymorphisms in the lncRNA *PRNCR1* might affect genetic susceptibility to GC. Therefore, we conducted a case--control study to elucidate the association between single nucleotide polymorphisms (SNPs) in *PRNCR1* and risk of developing GC in a Korean population. We further analyzed the impact of *PRNCR1* polymorphisms on GC risk in combination with various characteristics and clinical features, including age, sex, tumor differentiation, histologic type, T classification, lymph node metastasis (LNM), and tumor stage.

2. Results {#sec2-ijms-20-03355}
==========

2.1. Patient Characteristics and Single Nucleotide Polymorphisms (SNP) Selection {#sec2dot1-ijms-20-03355}
--------------------------------------------------------------------------------

The characteristics and clinical features of the 437 patients with GC and the 363 cancer-free controls are presented in [Table 1](#ijms-20-03355-t001){ref-type="table"}. There was a significant difference in the age and gender distribution between the two groups (*p* \< 0.001 and *p* \< 0.001, respectively). The mean age was 65.3 ± 11.1 years for GC patients and 58.1 ± 8.9 years for the controls. The proportion of male subjects was significantly higher in the group with GC (69.6%), whereas the number of female subjects was higher in the control group (67.2%). Of the 437 patients with diagnosed GC, more than half were classified as having the intestinal type (55.8%), making it the most common type, followed by the diffuse-type and the mixed-type. The majority of the patients did not show lymph node metastasis (LNM) (60.9%) and were classified as T1 (50.6%) and tumor stage I (58.8%). We selected five *PRNCR1* SNPs: rs1016343, rs13252298, rs7841060, rs16901946, and rs1456315, which have been previously associated with cancer.

2.2. Associations Between PRNCR1 SNPs and GC risk {#sec2dot2-ijms-20-03355}
-------------------------------------------------

The genotype frequencies of rs1016343, rs13252298, rs7841060, and rs16901946 were in Hardy--Weinberg equilibrium (HWE) for both the GC group (*p* = 0.772, *p* = 0.968, *p* = 0.668, and *p* = 0.821, respectively) and the control group (*p* = 0.591, *p* = 0.143, *p* = 0.610, and *p* = 0.978, respectively) ([Table 2](#ijms-20-03355-t002){ref-type="table"}). However, rs1456315 frequencies were not in HWE for either GC or controls (*p* \< 0.05). The rs1456315 was, therefore, excluded from the genotype analysis because of Hardy-Weinberg disequilibrium. LD coefficients (\|D'\|) were estimated among the four SNPs, and an absolute LD (\|D'\| = 1 and *r*^2^) was not found for any pair-wise combination among four SNPs using Haploview 4.0 software. To determine whether rs1016343, rs13252298, rs7841060, and rs16901946 were associated with a higher risk of GC or GC subgroups, we compared the genotypic frequencies between the GC group and the control group. After adjusting for age and gender, the recessive model indicated that the rs13252298 GG genotype was associated with an increased risk of intestinal-type gastric cancer (IGC) (OR = 1.92, 95% CI = 1.01--3.63, *p* = 0.045), as compared to the rs13252298 AA/AG genotypes; the remaining SNPs showed no significant associations ([Table 2](#ijms-20-03355-t002){ref-type="table"}).

2.3. Stratified Analysis for Four PRNCR1 SNPs {#sec2dot3-ijms-20-03355}
---------------------------------------------

To further estimate the possible correlation between the four SNPs and GC risk in GC subgroups, we performed stratified analyses based on various patient characteristics, including age, sex, LNM, T classification, and tumor stage. As shown in [Table 3](#ijms-20-03355-t003){ref-type="table"}, after adjusting for age and gender, our recessive model demonstrated that the rs1016343 TT genotype was significantly associated with a decreased risk of GC in subjects aged \<60 years showing LNM-negative results (odds ratio, OR = 0.29, 95% confidence interval, CI = 0.09--0.94, *p* = 0.038), when compared to the rs1016343 CC/CT genotypes. Moreover, according to the recessive model, the rs13252298 GG genotype was associated with an increased risk of GC for those aged ≥60 years showing LNM-positive results (OR = 2.80, 95% CI = 1.15--6.82, *p* = 0.024) and those aged ≥60 years in tumor stage III (OR = 3.39, 95% CI = 1.35--8.52, *p* = 0.009), as compared to the rs13252298 AA/AG genotypes. Furthermore, the dominant model showed that the rs16901946 combined genotype (AG/GG) had a significant association with increased risk of GC in subjects aged \<60 years in tumor stage III (OR = 2.38, 95% CI = 1.15--4.94, *p* = 0.020). The recessive model also showed that the rs16901946 GG genotype was associated with a decreased risk of GC (OR = 0.43, 95% CI = 0.19--0.98, *p* = 0.046) and IGC (OR = 0.38, 95% CI = 0.16--0.89, *p* = 0.026) in male subjects aged ≥60 years when compared to the rs16901946 AA/AG genotype. However, the association between polymorphisms in *PRNCR1* and tumor differentiation was not observed.

3. Discussion {#sec3-ijms-20-03355}
=============

To date, most studies, including GWAS and a meta-analysis, have reported on the association between genetic variations in *PRNCR1* and PC \[[@B18-ijms-20-03355],[@B19-ijms-20-03355],[@B20-ijms-20-03355],[@B21-ijms-20-03355]\]. However, little is known about the associations between *PRNCR1* polymorphisms and GC. Furthermore, results thus far have been inconsistent, and the genotyping methods have also varied \[[@B14-ijms-20-03355],[@B23-ijms-20-03355]\]. In this case--control study, we investigated the association between lncRNA *PRNCR1* polymorphisms and GC risk in a Korean population using a reliable TaqMan genotyping assay. We found that the rs13252298 GG genotype was associated with 1.92-times increased risk of IGC. Li et al. previously reported that there was an association between the rs13252298 AG genotype and GC in the Chinese population; in contrast, He et al. reported a lack of association between the rs13252298 polymorphism and GC in the Chinese population \[[@B14-ijms-20-03355],[@B23-ijms-20-03355]\]. Interestingly, our age-stratified analysis found that the rs1016343 TT genotype was associated with 0.92-times reduced risk of GC in subjects aged \<60 years showing LNM-negative results; the rs13252298 GG genotype was associated with 2.80- and 3.39-times increased risk of GC in subjects aged ≥60 years showing LNM-positive results and aged ≥60 years in tumor stage III, respectively. The rs16901946 AG/GG genotype was associated with 2.38-times increased risk of GC in subjects \<60 years in tumor stage III. However, He et al. described an association between the rs16901946 genotype and increased risk of GC in younger and tumor stage I+II subjects. Interestingly, in our study the rs1016343 TT genotype was associated with 0.29-times decreased risk of GC in those aged \<60 years showing LNM-negative results. Li et al. demonstrated an association between the rs1456315 GG genotype and a decreased risk of GC. However, we could not analyze an association because of the Hardy--Weinberg disequilibrium in either the GC group or the control group (*p* \< 0.05).

There are several limitations to our study. First, the sample size was too small to have statistical power for our stratified analyses. Second, although *Helicobacter pylori* is an independent risk factor \[[@B24-ijms-20-03355],[@B25-ijms-20-03355]\], we did not investigate its relevance with regard to the *PRNCR1* polymorphisms in GC risk because of ethical considerations. Third, we failed to explore whether there is an association between the genetic factors and smoking, drinking, and diet related to GC risk owing to lack of these data from the GC and control groups. Fourth, our study was performed in a Korean population. Thus, we should include other ethnic groups and a larger sample size to confirm our results. Future studies will require that we assess the influence of these factors on GC.

In conclusion, our study suggests that the *PRNCR1* rs13252298 and rs16901946 polymorphisms are associated with increased GC risk and may exacerbate the development of GC. Moreover, the *PRNCR1* rs1016343 polymorphism may contribute to a decreased risk of GC in those aged \<60 years showing LNM-negative results. Further studies are needed to validate our results in a larger population as well as in different ethnic groups.

4. Materials and Methods {#sec4-ijms-20-03355}
========================

4.1. Ethics Statement {#sec4dot1-ijms-20-03355}
---------------------

The present study was conducted in accordance with the Declaration of Helsinki and was reviewed and approved by the Ethics Committee of the institutional review board of Chungnam National University Hospital on 23 July 2017. Informed consent was provided by all subjects when they were enrolled.

4.2. Study Subjects {#sec4dot2-ijms-20-03355}
-------------------

In total, 437 GC patients and 357 healthy controls were enrolled in this study. The blood samples used in this study were provided by the Chungnam National Hospital Biobank, a member of the National Biobank of Korea, which is supported and audited by the Ministry of Health and Welfare of Korea. All individuals enrolled in this study provided their written informed consent for blood collection and use. GC patients were recruited from the outpatient clinic at the Chungnam National University Hospital, and classified according to the Lauren's classification \[[@B26-ijms-20-03355]\]. The subjects for the control group were randomly selected among healthy volunteers visiting the Chungnam National University Hospital medical center for their annual physical examinations; only individuals who had no history of cancer were included.

4.3. DNA Isolation and Genotyping {#sec4dot3-ijms-20-03355}
---------------------------------

Genomic DNA was isolated from the peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's instructions. Five SNPs (rs1016343, rs13252298, rs7841060, rs16901946, and rs1456315) in *PRNCR1* were selected based on previous reports \[[@B14-ijms-20-03355],[@B19-ijms-20-03355],[@B20-ijms-20-03355],[@B23-ijms-20-03355],[@B24-ijms-20-03355],[@B25-ijms-20-03355]\] and genotyped using the Applied Biosystems TaqMan SNP Genotyping Assay with the StepOnePlus Real-time PCR System (Applied Biosystems, Foster City, CA, USA).

4.4. Statistical Analysis {#sec4dot4-ijms-20-03355}
-------------------------

Hardy--Weinberg equilibrium (HWE) for each SNP in the control groups was evaluated using the chi-squared test. A pair-wise comparison of biellelic loci was employed for the analyses of linkage disequilibrium (LD) using Haploview software version 4.0 (the Broad Institute, Cambridge, MA, USA). Differences in age and gender between the GC and control groups were calculated using the two-sided Pearson chi-squared test and the Mann--Whitney *U*-test. Two genetic models (dominant and recessive models) were used to analyze the associations. A binary logistic regression was used to estimate the GC risk according to odds ratios (ORs) and 95% confidence intervals (CIs). The association analysis was adjusted by age and sex, which were included in the model as covariates. All statistical analyses were performed using the SPSS (SPSS Inc., Chicago, IL, USA), version 20.0 for Windows. *p* \<0.05 was considered statistically significant.
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###### 

Characteristics and clinical features of the gastric cancer group and the control group.

  Variables                   Gastric Cancers     Controls           *p*
  --------------------------- ------------------- ------------------ -------------
  Age (years) (mean ± SD)     437 (65.3 ± 11.1)   357 (58.1 ± 8.9)   \<0.001 \*
  \<60                        185 (42.3)          186 (52.1)         0.007 ^†^
  ≥60                         252 (57.7)          171 (47.9)         
  Gender (%)                                                         
  Male                        304 (69.6)          117 (32.8)         \<0.001 ^†^
  Female                      133 (30.4)          240 (67.2)         
  Tumor differentiation                                              
  Differentiated              208 (47.6)                             
  Undifferentiated            190 (43.5)                             
  Missing                     39 (8.9)                               
  Histological type (%)                                              
  Intestinal                  244 (55.8)                             
  Diffuse                     140 (32.1)                             
  Mixed                       53 (12.1)                              
  T classification (%)                                               
  T1                          221 (50.6)                             
  T2                          59 (13.5)                              
  T3                          16 (3.6)                               
  T4                          141 (32.3)                             
  Lymph node metastasis (%)                                          
  Negative                    266 (60.9)                             
  Positive                    171 (39.1)                             
  Tumor stage (%)                                                    
  I (A+B)                     257 (58.8)                             
  II (A+B)                    50 (11.5)                              
  III (A+B+C)                 130 (29.7)                             

SD, standard deviation. \* Mann--Whitney *U*-test. ^†^ Two-sided Pearson's chi-squared test.

ijms-20-03355-t002_Table 2

###### 

Genotype and allelic frequencies of *PRNCR1* polymorphisms in subjects and their association with GC risk.

  Genotype         CON          GC vs. CON   IGC vs. CON         DGC vs. CON                                                                                 
  ---------------- ------------ ------------ ------------------- ------------- ------------ ------------------- ----------- ------------ ------------------- -------
  rs1016343                                                                                                                                                  
  Codominant                                                                                                                                                 
    CC             171 (47.9)   209 (47.8)   1                                 119 (48.5)   1                               62 (44.6)    1                   0.661
    CT             158 (44.3)   191 (43.7)   0.94 (0.69--1.29)   0.709         106 (43.3)   0.94 (0.64--1.38)   0.756       66 (47.5)    1.10 (0.72--1.68)   0.892
    TT             28 (7.8)     37 (8.5)     0.88 (0.49--1.56)   0.654         20 (8.2)     0.84 (0.42--1.67)   0.612       11 (7.9)     0.95 (0.44--2.06)   
  Dominant                                                                                                                                                   
  CC               171 (47.9)   209 (47.8)   1                                 119 (48.6)   1                               62 (44.6)    1                   0.727
  CT + TT          186 (52.1)   228 (52.2)   0.93 (0.69--1.26)   0.645         126 (51.4)   0.92 (0.64--1.33)   0.672       77 (55.4)    1.08 (0.72--1.61)   
  Recessive                                                                                                                                                  
  CC + CT          329 (92.2)   406 (91.5)   1                                 225 (91.8)   1                               128 (92.1)   1                   0.790
  TT               28 (8.7)     37 (8.5)     0.90 (0.52--1.57)   0.718         20 (8.2)     0.86 (0.44--1.68)   0.659       11 (7.9)     0.90 (0.43--1.91)   
  HWE              0.591        0.772                                                                                                                        
  **rs13252298**                                                                                                                                             
  Codominant                                                                                                                                                 
    AA             158 (44.3)   214 (49.0)   1                                 122 (49.6)   1                               67 (48.6)    1                   0.450
    AG             171 (47.9)   182 (41.6)   0.90 (0.66--1.24)   0.518         97 (39.4)    0.87 (0.59--1.29)   0.497       61 (44.2)    0.85 (0.56--1.30)   0.854
    GG             28 (7.8)     41 (9.4)     1.36 (0.77--2.40)   0.285         27 (11.0)    1.80 (0.93--3.49)   0.084       10 (7.2)     0.93 (0.42--2.06)   
  Dominant                                                                                                                                                   
  AA               158 (44.3)   214 (49.0)   1                                 122 (49.6)   1                               67 (48.6)    1                   0.469
    AG + GG        199 (55.7)   223 (51.0)   0.96 (0.71--1.31)   0.805         124 (50.4)   0.99 (0.69--1.43)   0.954       71 (51.4)    0.86 (0.57--1.30)   
  Recessive                                                                                                                                                  
  AA+AG            329 (92.2)   396 (90.6)   1                                 219 (89.0)   1                               128 (92.8)   1                   0.982
  GG               28 (7.8)     41 (9.4)     1.43 (0.83--2.47)   0.193         27 (11.0)    1.92 (1.01--3.63)   **0.045**   10 (7.2)     1.01 (0.47--2.18)   
  HWE              0.143        0.968                                                                                                                        
  rs7841060                                                                                                                                                  
  Codominant                                                                                                                                                 
    TT             169 (47.4)   204 (46.7)   1                                 116 (47.5)   1                               61 (43.5)    1                   0.556
    TG             159 (44.5)   195 (44.6)   0.96 (0.70--1.31)   0.794         108 (44.3)   0.96 (0.65--1.40)   0.814       68 (48.6)    1.14 (0.75--1.73)   0.842
    GG             29 (8.1)     38 (8.7)     0.88 (0.50--1.55)   0.647         20 (8.2)     0.82 (0.41--1.64)   0.578       11 (7.9)     0.92 (0.43--2.00)   
  Dominant                                                                                                                                                   
  TT               169 (47.3)   204 (46.7)   1                                 116 (47.5)   1                               61 (43.6)    1                   0.643
  TG + GG          188 (52.7)   233 (53.3)   0.95 (0.70--1.28)   0.716         128 (52.5)   0.93 (0.65--1.35)   0.711       79 (56.4)    1.10 (0.73--1.65)   
  Recessive                                                                                                                                                  
  TT + TG          328 (91.9)   399 (91.3)   1                                 224 (91.8)   1                               129 (92.1)   1                   0.705
  GG               29 (8.1)     38 (8.7)     0.89 (0.52--1.54)   0.688         20 (8.2)     0.84 (0.43--1.63)   0.609       11 (7.9)     0.87 (0.41--1.82)   
  HWE              0.610        0.668                                                                                                                        
  rs16901946                                                                                                                                                 
  Codominant                                                                                                                                                 
    AA             178 (49.9)   208 (47.6)   1                                 117 (48.0)   1                               68 (48.6)    1                   0.506
    AG             147 (41.1)   191 (43.7)   1.21 (0.88--1.66)   0.245         105 (43.0)   1.26 (0.85--1.85)   0.253       62 (44.3)    1.15 (0.76--1.76)   0.643
    GG             32 (9.0)     38 (8.7)     0.84 (0.49--1.46)   0.539         22 (9.0)     0.78 (0.40--1.49)   0.445       10 (7.1)     0.83 (0.38--1.83)   
  Dominant                                                                                                                                                   
  AA               178 (49.9)   208 (47.6)   1                                 117 (48.0)   1                               68 (48.6)    1                   0.658
  AG + GG          179 (50.1)   229 (52.4)   1.13 (0.84--1.54)   0.414         127 (52.0)   1.15 (0.79--1.65)   0.468       72 (51.4)    1.10 (0.73--1.64)   
  Recessive                                                                                                                                                  
  AA + AG          325 (91.0)   399 (91.3)   1                                 222 (91.0)   1                               130 (92.9)   1                   0.516
  GG               32 (9.0)     38 (8.7)     0.77 (0.45--1.31)   0.338         22 (9.0)     0.70 (0.37--1.32)   0.269       10 (7.1)     0.78 (0.36--1.67)   
  HWE              0.978        0.821                                                                                                                        

CON, control; GC, gastric cancer; IGC, intestinal-type gastric cancer; DGC, diffuse-type gastric cancer; AOR, adjusted odds ratio; CI, confidence interval; HWE, Hardy--Weinberg equilibrium. ^a^ Adjusted for age and gender. The significant results are in bold.
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###### 

Stratified analysis of *PRNCR1* polymorphisms in GC patients and controls by age.

  SNP              Variable              GC vs. CON                                                                                   
  ---------------- --------------------- ------------ -------- ------------------- ----------- -------- -------- -------------------- -----------
  **rs1016343**    Gender (M)            76/56        28/17    0.93 (0.46--1.90)   0.849       8/124    6/39     0.43 (0.14--1.32)    0.140
  Age              Gender (F)            27/28        68/73    1.00 (0.53--1.90)   0.992       2/53     9/132    0.40 (0.08--2.07)    0.276
  \<60             IGC                   43/44        96/90    0.72 (0.38--1.37)   0.320       4/83     15/171   0.34 (0.10--1.19)    0.090
                   DGC                   47/30        96/90    1.43 (0.79--2.56)   0.236       4/73     15/171   0.50 (0.15--1.63)    0.248
                   **LNM (−)**           73/50        96/90    1.28 (0.74--2.23)   0.380       5/118    15/171   0.29 (0.09--0.94)    **0.038**
                   LNM (+)               30/34        96/90    0.71 (0.38--1.33)   0.284       5/59     15/171   0.76 (0.25--2.34)    0.634
                   Tumor stage I + II    84/60        96/90    1.19 (0.70--2.02)   0.512       8/136    15/171   0.45 (0.17--1.24)    0.123
                   Tumor stage III       19/24        96/90    0.61 (0.30--1.26)   0.184       2/41     15/171   0.40 (0.08--1.90)    0.248
  ≥60              Gender (M)            36/38        91/85    1.14 (0.66--1.97)   0.646       21/155   6/68     1.48 (0.56--3.88)    0.426
                   Gender (F)            34/40        54/43    1.14 (0.66--1.97)   0.144       6/68     7/90     1.48 (0.56--3.88)    0.663
                   IGC                   83/75        90/81    1.09 (0.67--1.76)   0.727       16/142   13/158   1.39 (0.59--3.26)    0.453
                   DGC                   30/32        90/81    0.81 (0.45--1.48)   0.495       7/55     13/158   1.40 (0.51--3.84)    0.514
                   LNM (−)               76/69        90/81    0.99 (0.62--1.59)   0.967       14/131   13/158   1.28 (0.55--3.01)    0.566
                   LNM (+)               49/56        90/81    0.80 (0.47--1.36)   0.409       13/92    13/158   1.42 (0.57--3.53)    0.446
                   Tumor stage I + II    83/83        90/81    0.92 (0.58--1.45)   0.706       17/149   13/158   1.40 (0.62--3.15)    0.418
                   Tumor stage III       42/42        90/81    0.90 (0.51--1.58)   0.703       10/74    13/158   1.25 (0.47--3.37)    0.658
  **rs13252298**   Gender (M)            69/63        27/18    0.75 (0.37--1.49)   0.405       8/124    1/44     2.69 (0.32--22.47)   0.360
  Age              Gender (F)            33/21        89/53    0.88 (0.46--1.71)   0.716       6/48     16/126   0.95 (0.34--2.63)    0.916
  \<60             IGC                   45/42        116/71   0.75 (0.40--1.40)   0.369       10/77    17/170   2.42 (0.83--7.00)    0.104
                   DGC                   44/32        116/71   0.82 (0.46--1.48)   0.517       4/72     17/170   0.78 (0.24--2.54)    0.680
                   LNM (−)               67/54        116/71   0.86 (0.49--1.49)   0.590       10/111   17/170   1.26 (0.47--3.35)    0.645
                   LNM (+)               35/30        116/71   0.72 (0.39--1.34)   0.297       4/61     17/170   1.13 (0.34--3.75)    0.847
                   Tumor stage I + II    77/65        116/71   0.81 (0.48--1.37)   0.434       12/130   17/170   1.51 (0.60--3.81)    0.382
                   Tumor stage III       25/19        116/71   0.82 (0.41--1.66)   0.585       2/42     17/170   0.69 (0.15--3.28)    0.645
  ≥60              Gender (M)            79/95        32/41    1.04 (0.59--1.81)   0.898       18/156   5/68     1.77 (0.62--5.06)    0.289
                   Gender (F)            42/35        51/46    0.96 (0.50--1.87)   0.912       9/68     6/91     1.83 (0.54--6.21)    0.332
                   IGC                   79/80        83/87    1.07 (0.66--1.73)   0.780       17/142   11/159   1.73 (0.73--4.10)    0.210
                   DGC                   27/35        83/87    0.87 (0.47--1.59)   0.646       6/56     11/159   2.19 (0.74--6.48)    0.157
                   LNM (−)               71/75        83/87    1.01 (0.63--1.62)   0.967       12/134   11/159   1.43 (0.58--3.56)    0.442
                   **LNM (+)**           50/55        83/87    1.07 (0.62--1.82)   0.817       15/90    11/159   2.80 (1.15--6.82)    **0.024**
                   Tumor stage I + II    80/86        83/87    1.01 (0.64--1.60)   0.975       14/152   11/159   1.37 (0.56--3.32)    0.493
                   **Tumor stage III**   41/44        83/87    1.08 (0.61--1.92)   0.782       13/72    11/159   3.39 (1.35--8.52)    **0.009**
  rs7841060        Gender (M)            76/52        28/16    0.93 (0.45--1.92)   0.847       10/118   6/38     0.55 (0.19--1.64)    0.286
  Age              Gender (F)            27/30        69/73    0.94 (0.50--1.76)   0.838       2/55     10/132   0.37 (0.07--1.88)    0.230
  \<60             IGC                   43/43        97/89    0.68 (0.36--1.28)   0.232       5/81     16/170   0.43 (0.13--1.37)    0.153
                   DGC                   47/30        97/89    1.39 (0.77--2.50)   0.272       4/73     16/170   0.48 (0.15--1.57)    0.224
                   LNM (−)               71/49        97/89    1.19 (0.68--2.08)   0.535       6/114    16/170   0.34 (0.12--1.03)    0.056
                   LNM (+)               32/33        97/89    0.74 (0.39--1.37)   0.333       6/59     16/170   0.86 (0.30--2.47)    0.778
                   Tumor stage I + II    82/59        97/89    1.11 (0.66--1.88)   0.695       9/132    16/170   0.49 (0.19--1.29)    0.147
                   Tumor stage III       21/23        97/89    0.67 (0.33--1.36)   0.264       3/41     16/170   0.55 (0.14--2.11)    0.384
  ≥60              Gender (M)            93/83        36/37    1.14 (0.66--1.98)   0.644       20/156   6/67     1.35 (0.51--3.56)    0.544
                   Gender (F)            37/39        55/43    0.74 (0.38--1.44)   0.378       6/70     7/91     1.31 (0.39--4.42)    0.668
                   IGC                   85/73        91/80    1.15 (0.71--1.86)   0.577       15/143   13/158   1.26 (0.53--3.01)    0.602
                   DGC                   32/31        91/80    0.90 (0.50--1.64)   0.737       7/56     13/158   1.38 (0.50--3.78)    0.536
                   LNM (−)               79/67        91/80    1.08 (0.67--1.73)   0.753       14/132   13/158   1.26 (0.54--2.95)    0.598
                   LNM (+)               51/55        91/80    0.82 (0.48--1.39)   0.450       12/94    13/158   1.22 (0.48--3.09)    0.676
                   Tumor stage I + II    85/81        91/80    0.98 (0.62--1.55)   0.922       16/150   13/158   1.28 (0.56--2.93)    0.554
                   Tumor stage III       45/41        91/80    0.95 (0.54--1.67)   0.861       10/76    13/158   1.21 (0.45--3.25)    0.702
  **rs16901946**   Gender (M)            66/63        17/27    1.48 (0.72--3.02)   0.282       14/115   3/41     1.64 (0.44--6.05)    0.462
  Age              Gender (F)            29/26        68/75    1.35 (0.71--2.57)   0.364       1/54     9/134    0.34 (0.04--2.76)    0.312
  \<60             IGC                   45/40        85/102   1.75 (0.92--3.32)   0.088       10/75    12/175   1.38 (0.46--4.11)    0.562
                   DGC                   39/38        85/102   1.20 (0.68--2.14)   0.533       2/75     12/175   0.35 (0.07--1.81)    0.210
                   LNM (−)               58/62        85/102   1.14 (0.66--1.98)   0.638       10/110   12/175   0.95 (0.33--2.74)    0.920
                   LNM (+)               37/27        85/102   1.78 (0.96--3.32)   0.069       5/59     12/175   1.09 (0.33--3.58)    0.883
                   Tumor stage I+II      68/73        85/102   1.08 (0.64--1.83)   0.766       12/129   12/175   1.01 (0.37--2.76)    0.989
                   **Tumor stage III**   27/16        85/102   2.38 (1.15--4.94)   **0.020**   3/40     12/175   1.03 (0.26--4.08)    0.972
  ≥60              **Gender (M)**        91/85        40/33    0.91 (0.52--1.58)   0.734       15/161   12/61    0.43 (0.19--0.98)    **0.046**
                   Gender (F)            43/34        54/43    1.14 (0.58--2.22)   0.709       8/69     8/89     1.33 (0.41--4.25)    0.635
                   **IGC**               82/77        94/76    0.94 (0.58--1.52)   0.797       12/147   20/150   0.38 (0.16--0.89)    **0.026**
                   DGC                   47/30        94/76    1.43 (0.79--2.56)   0.236       4/73     20/150   0.50 (0.15--1.63)    0.248
                   LNM (−)               80/66        94/76    1.05 (0.65--1.69)   0.841       16/130   20/150   0.69 (0.32--1.47)    0.336
                   LNM (+)               54/53        94/76    0.85 (0.50--1.44)   0.538       7/100    20/150   0.39 (0.15--1.06)    0.064
                   Tumor stage I + II    92/75        94/76    1.04 (0.66--1.65)   0.871       18/149   20/150   0.65 (0.31--1.36)    0.249
                   Tumor stage III       42/44        94/76    0.82 (0.47--1.45)   0.495       5/81     20/150   0.37 (0.12--1.12)    0.078

GC, gastric cancer; CON, control; ht, heterozygous; mt, mutant; wt, wild-type; SNP, single nucleotide polymorphism; AOR, adjusted odds ratio; CI, confidence interval; M, male; F, female; IGC, intestinal-type gastric cancer; DGC, diffuse-type gastric cancer; LNM; lymph node metastasis. ^a^ Adjusted for age and gender. The significant results are in bold.

[^1]: These authors contributed equally to this work.
